Donald Hayden
Chairman

Robert V. Gunderson, Jr.
Senior Partner
Gunderson, Dettmer, Stough,
Villeneuve, Franklin & Hachigian, LLP

Jeffrey S. Hatfield
Chief Executive Officer

Charles Newhall, III
General Partner, New Enterprise Associates

Bryan Roberts, Ph.D.
General Partner, Venrock Associates

James Tananbaum, M.D.
Co-founder and Managing Partner, Prospect Venture Partners

Peter Barrett
Senior Partner, Atlas Venture

Board of Directors, Observers

Jeffrey L. Edwards
Executive Vice President, Finance and Business Development,
Chief Financial Officer, Allergan Corporation

Julie Eskay-Eagle,
Managing Director, September Ventures, LLC

Charles Scott,
Intel Capital, Intel Corporation

Donald Hayden, Chairman. Mr. Hayden brings to Vitae the experiences, insights and perspective gained during a highly-successful 25 year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company. Most recently, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing. Prior to that, Mr. Hayden has held a number of senior management positions including vice president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy, e-business, Investor Relations and Competitive Intelligence; and executive vice president of the Health Care Group. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

Robert V. Gunderson, Jr., Senior Partner of Gunderson Dettmer. Mr. Gunderson is a recognized authority in the areas of emerging growth companies and venture capital. Mr. Gunderson holds a J.D. from the University of Chicago where he was Executive Editor of The University of Chicago Law Review and is currently a member of the Law School's Visiting Committee. Mr. Gunderson currently serves as a director of a number of private companies, including Theravance. Mr. Gunderson also received an M.B.A. in finance from The Wharton School, University of Pennsylvania and an M.A. from Stanford University.

Jeffrey S. Hatfield, Chief Executive Officer. Prior to joining VITAE PHARMACEUTICALS, Inc., Mr. Hatfield spent 19 years at Bristol-Myers Squibb, Inc. in a variety of operating positions of increasing responsibility. Most recently, he was Senior Vice President of one of BMS's most successful Divisions, the $1 billion Virology/Immunology Division, where Mr. Hatfield was responsible for sales, marketing, policy and medical strategy within the HIV, hepatitis and RA therapeutic categories. Previously, he held positions including President and General Manager, BMS-Canada, and Vice President, Managed Health Care. Mr. Hatfield holds a BS in Pharmacy from Purdue University and an MBA from the Wharton School, University of Pennsylvania.

Charles W. Newhall III, Co-founder of New Enterprise Associates. Chuck's investment activities focus on healthcare service, healthcare information service and biopharmaceutical companies. His board memberships include AMERIGROUP, CompHealth, Vitae Pharmaceuticals, ElderHealth, Essential Therapeutics, HealthSouth Corp., LifeMetrix, MedCenterDirect.com, PatientKeeper, Sensors for Medicine & Science, TargetRx and Vela Pharmaceuticals. He works closely with MediSphere Health Partners. His prior board memberships include Chomerics, Genetic Therapy, Life Technologies, Russ Pharmaceuticals, Scandipharm, Sepracor, Surgical Health and Zymark Corporation. He is a founder and Chairman Emeritus of the Mid-Atlantic Venture Association. Before co-founding NEA, Chuck was a Vice President with T. Rowe Price Associates and Vice President of their New Horizons Fund. He received a Masters in Business Administration from the Harvard University Graduate School of Business and a Bachelor of Arts in English Literature with honors from the University of Pennsylvania.

Bryan Roberts, Ph.D., General Partner, Venrock Associates. Dr. Roberts joined Venrock in 1997 and is now a General Partner involved with the firm's activities in health care. Dr. Roberts is primarily responsible for Venrock's investments in Illumina and Nanosys, and serves on the boards of Athenahealth, First Genetic Trust, Microbia, Surface Logix and Xenoport. Prior to joining Venrock, Dr. Roberts received his Ph.D. in chemistry and chemical biology at Harvard University and from 1989-1992, worked at Kidder Peabody & Co., Inc. Dr. Roberts graduated from Dartmouth College, where he obtained a B.A. in chemistry.

James Tananbaum, M.D., Co-founder and Managing Partner Prospect Venture Partners. Dr. Tananbaum has founded and/or led financings in several substantial healthcare companies during the past ten years. He was the founding CEO of Theravance (formerly Advanced Medicine, Inc.) and founder and acting CEO of GelTex Pharmaceuticals (purchased by Genzyme, Inc.) and Infinity Pharmaceuticals, Inc. He has led investments in Intensiva HealthCare Corporation, NovaMed EyeCare Management Healtheon/WebMD and Amerigroup. Earlier in his career, Dr. Tananbaum held a variety of line operating management positions at Merck & Company, Inc. and was a partner at Sierra Ventures. He is a founding member of the Harvard/MIT Health Sciences and Technology Advisory Group, a member of the Young Presidents' Organization and the World Economic Forum Global Leaders of Tomorrow. He received an M.D. from Harvard Medical School, an M.B.A from Harvard Business School, and B.S.E.E. and B.S. degrees from Yale University.

Peter Barrett, Senior Partner, Atlas Ventures. Peter Barrett is a Senior Partner in the life sciences sector, and joined Atlas Venture in 2002. Previously, he was a co-founder and Executive Vice President and Chief Business Officer of Celera Genomics, positions he had held since 1998. Within two years of the founding of the company, Celera announced the first successful sequencing of the human genome. Peter currently sits on the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University and is a member of the Partners Healthcare Research Accelerator Program. Peter's past board appointments include Chairman of the Board of the Analytical and Life Science System Association, HuBit Genomix, Genecore, Roche Strategic Alliance, and Sciex Joint Venture. He currently sits on the boards of Alnylam and Momenta Pharmaceuticals.

Jeffrey L. Edwards, Executive Vice President, Finance and Business Development, Chief Financial Officer, Allergan Corporation. Mr. Edwards has been with Allergan since 1993 and previously served as Senior Vice President, Treasury, Tax, and Investor Relations where he was instrumental in developing and executing Allergan's financial strategies to support Allergan's expanding needs. Mr. Edwards is also the The Allergan Foundation's Chief Financial Officer. Prior to Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior level positions in the credit and business development functions.

Julie Eskay-Eagle, Managing Director, September Ventures, LLC. Ms. Eskay-Eagle is Managing Director of September Ventures, LLC, based in Cos Cob, CT, which manages Direct Investments for The Wellcome Trust. Ms. Eskay-Eagle was a full time employee of The Wellcome Trust from 2001-2004 and established their Direct Investment Program in London, UK. Prior to joining the Trust Ms. Eskay-Eagle was a Vice President with Lazard Freres in Health Care Investment Banking and a founding member of Lazard Technology Partners. Before joining Lazard, she was a Health Care Specialist with McKinsey & Co. in New York. Ms. Eskay-Eagle has a bachelor's degree in Biomedical Ethics from Cornell University and an MBA from Columbia University.

Charles Scott, Intel Capital, Intel Corporation. Charles Scott manages the tri-state area (New York, New Jersey, Pennsylvania) investment strategy for Intel Capital, Intel Corporation's venture investment arm. In this role, he evaluates a broad range of deals in a number of investment sectors, including enterprise hardware/software, digital home, digital healthcare and wireless mobility. In his nine years at Intel, Charles has held a variety of management positions, including running international business development and marketing in the Enterprise Products Group, serving as chief of staff to the General Manager of Intel's Mobile Products Group, and managing Intel's worldwide strategic engagement with General Electric and NASDAQ. Prior to joining Intel, Charles worked in New York City at the U.S. Council for International Business, where he lobbied international governmental organizations on behalf of U.S. high tech companies. Charles has an undergraduate degree from Vanderbilt University and a Masters degree from the Fletcher School at Tufts and Harvard Universities. He speaks German and Japanese.

[back to top]